Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

August 13th 2021

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Making the Most of Molecular Testing in Breast Cancer

August 12th 2021

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast Cancer

August 12th 2021

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

NICE Recommends Abemaciclib for HR+/HER2– Advanced Breast Cancer

August 12th 2021

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of abemaciclib in the treatment of adult patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Expanding Armamentarium Allows for Tailored Approaches in Breast Cancer, in Especially Older Patients

August 12th 2021

The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.

Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer

August 11th 2021

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Future Directions for the Management of HR+ Breast Cancer

August 11th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical Practice

August 11th 2021

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Gaps in Treatment for HER2+ MBC With Brain Metastasis

August 10th 2021

Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.

Case Scenario: 55-Year-Old Woman With HER2+ MBC and Brain Metastasis

August 10th 2021

A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.

Dr. Labaki on Disparities in Mammography Screenings During the COVID-19 Pandemic

August 9th 2021

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

Smarter Screening, Risk Assessments Are Key to Eliminating Racial Disparities in Breast Cancer Outcomes

August 9th 2021

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.

Using CDK4/6 Inhibitors in Early Stage HR+ Breast Cancer

August 4th 2021

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Early Stage HR+ Breast Cancer: Optimizing Multigene Assays

August 4th 2021

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

Treatment Options for HER2+ MBC With Brain Metastasis

August 3rd 2021

Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.

Brain Metastasis in HER2+ MBC

August 3rd 2021

Recommendations for screening patients with HER2-positive metastatic breast cancer for signs of brain metastasis as a consequence of current rates of prevalence.

CDK4/6 Inhibitors Improve OS, but Sequencing Strategies Continue to Form in HR+/HER2- Breast Cancer

August 2nd 2021

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Pegram Points to Progress, Ongoing Efforts in Advanced HER2+ Breast Cancer

August 2nd 2021

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

Soliman Details Ongoing Novel Immunotherapeutic Research Efforts at Moffitt, Recent Developments in Breast Cancer

August 2nd 2021

Moffitt Cancer Center is currently working to develop a host of novel therapeutic treatments within the breast cancer space, from immunotherapeutics to personalized cancer vaccines.

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

July 30th 2021

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.